Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug that is approved as
adjunctive therapy in adults with focal-onset seizures. Following oral administration, ESL is …

Eslicarbazepine acetate (Aptiom®) is a once-daily, orally administered antiepileptic drug
(AED) approved previously in the EU, USA and several other countries for use as adjunctive …

Abstract Eslicarbazepine acetate (Aptiom®, Zebinix®) is approved for the adjunctive
treatment of partial-onset seizures in adults aged≥ 18 years. Adjunctive therapy with oral …

Objective To assess the effectiveness and tolerability of eslicarbazepine acetate (ESL)
monotherapy in routine clinical practice for the treatment of focal‐onset seizures. Methods …

Introduction: Eslicarbazepine acetate (ESL) is a third generation AED structurally related to
carbamazepine and oxcarbazepine, but without several of the drawbacks associated with …

Purpose: To evaluate the long‐term efficacy and safety of once daily eslicarbazepine
acetate (ESL) as adjunctive therapy for partial‐onset seizures in adults with epilepsy …

Introduction: Up to 30% of the patients diagnosed with epilepsy will continue suffering from
seizures despite treatment with antiepileptic drugs, either in monotherapy or polytherapy …

Objective To assess seizure control and tolerability of eslicarbazepine acetate (ESL) as
adjunctive therapy to one baseline antiepileptic drug (AED), in adults with partial‐onset …

Epilepsy is a common neurological disorder. Despite a broad range of commonly used
antiepileptic drugs, approximately 30% of patients with epilepsy have drug resistance or …

Objectives–To evaluate the efficacy and safety of eslicarbazepine acetate (ESL) as
adjunctive therapy in adults with partial‐onset seizures. Material and methods–Double …